The Pharmacy Times® Psoriatic Arthritis resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
The updated label includes new evidence that the treatment significantly impedes the progression of joint structural damage at 24 weeks compared to placebo for patients with active psoriatic arthritis.
The label update includes new evidence that the treatment significantly impedes the progression of joint structural damage at 24 weeks compared to placebo for patients with active psoriatic arthritis.
Risankizumab shows promise as an important treatment option for people living with plaque psoriasis.
Ron Lanton III, Esq, President, True North Political Solutions, makes predictions about how dealings with biosimilars may change in 2018.
Tofacitinib (Xeljanz/Xeljanz XR) improves disease severity for patients with psoriatic arthritis.
Up to 90% of patients with psoriasis develop plaque on their nails, palms of the hands, and soles of the feet.
Hay fever and asthma are dependent on allergens that stimulate the immunoglobulin E pathway, which is not the case with atopic dermatitis.
Ixekizumab found to provide significant improvement in joint symptoms for patients not previously treated with a biologic disease-modifying antirheumatic drug.
Patients with moderate-to-severe nail psoriasis treated with secukinumab experienced significant improvement in the Nail Psoriasis Severity Index.
Secukinumab (Cosentyx) treatment observed to improve the signs and symptoms of psoriatic arthritis.
New Drug Applications filed for halobetasol propionate and tazarotene lotion, a topical treatment for plaque psoriasis.
Treatment for psoriatic arthritis may impact symptoms and patient-reported outcomes.